BioCentury
ARTICLE | Clinical News

ATIR101: Ph II amended

December 30, 2016 1:38 AM UTC

Kiadis will drop the second infusion of ATIR101 given 70-74 days after HSCT from a haploidentical donor in the open-label, international Phase II CIR-AIR-008 trial based on an independent DSMB recommendation. The trial will continue with the 1 infusion of ATIR101 given 28-32 days after HSCT. The recommendation was based on “various grades of GvHD,” including grade 3/4 GvHD, in “some” of the 6 patients treated with the second infusion. Kiadis completed recruitment of 15 patients, of which 10 received treatment...

BCIQ Company Profiles

Kiadis Pharma N.V.